Relationship between the intratumor pharmacokinetics and antitumor effect of the payload eribulin in the novel antibody-drug conjugate MORAb-202

被引：0
|
作者：
Koganemaru, S. [1 ]
Fuchigami, H. [2 ]
Tsugawa, H. [2 ]
Kuboki, Y. [1 ]
Furuuchi, K. [3 ]
Uenaka, T. [3 ]
Doi, T. [1 ]
Yasunaga, M. [2 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Expt Therapeut, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
[3] Eisai Inc, Epochal Precis Anticanc Therapeut EPAT, Exton, PA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
242
引用
收藏
页码：S87 / S87
页数：1
相关论文
共 50 条
  • [21] Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigen
    Shinmi, Daisuke
    Masuda, Kazuhiro
    CANCER SCIENCE, 2018, 109 : 332 - 332
  • [22] Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma
    Capone, Emily
    Piccolo, Enza
    Fichera, Imma
    Ciufici, Paolo
    Barcaroli, Daniela
    Sala, Arturo
    De laurenzi, Vincenzo
    Iacobelli, Valentina
    Iacobelli, Stefano
    Sala, Gianluca
    ONCOTARGET, 2017, 8 (36) : 60368 - 60377
  • [23] Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer
    Li, Lan
    Cao, Jiawei
    Chen, Chunyan
    Qin, Yaqian
    He, Licai
    Gu, Haihua
    Wu, Guang
    HELIYON, 2023, 9 (04)
  • [24] Dose optimization for MORAb-202, an antibody-drug conjugate (ADC) highly selective for folate receptor-alpha (FRα), using population pharmacokinetic (PPK) and exposure-response (E-R) efficacy and safety analyses.
    Hayato, Seiichi
    Hamuro, Lora
    Nomoto, Maiko
    Nishio, Shin
    Yonemori, Kan
    Yunokawa, Mayu
    Matsumoto, Koji
    Takehara, Kazuhiro
    Hasegawa, Kosei
    Hirashima, Yasuyuki
    Kato, Hidenori
    Shimizu, Toshio
    Ikezawa, Hiroki
    Otake, Yohei
    Miura, Takuma
    Zhao, Yue
    Zhu, Li
    Camacho, Trixia
    Dumitru, Calin Dan
    Yasuda, Sanae
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] MI130004, an antibody-drug conjugate including a novel payload of marine origin: Evidences of in vivo activity
    Aviles, P. M.
    Guillen, M. J.
    Dominguez, J. M.
    Munoz-Alonso, M. J.
    Garcia-Fernandez, L. F.
    Garranzo, M.
    Martinez, V.
    Francesch, A.
    Munt, S.
    Galmarini, C. M.
    Cuevas, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 164 - 164
  • [26] Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite
    Tu, Ya-Ping
    Hanze, Eva
    Zhu, Fengying
    Lagraauw, H. Maxime
    Sloss, Callum M.
    Method, Michael
    Esteves, Brooke
    Westin, Eric H.
    Berkenblit, Anna
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (02) : 568 - 581
  • [27] Preclinical study of a novel anti-CLEC12A antibody-drug conjugate with a glucuronide-protected pyrrolobenzodiazepine payload
    Jung, Jinwon
    Kim, Juhee
    Lee, Bora
    Kwon, Jung A.
    Lee, Suyoun
    Yoo, Byeongmin
    Ko, Minji
    Ryu, Ilhwan
    Yeom, Donghoon
    Lee, Kyoungjae
    Eom, Jaehyun
    Lee, Hanbyul
    Ahn, Jinhyung
    Sung, Eunsil
    You, Weonkyoo
    Lee, Sang Hoon
    Kim, Myeong Joo
    Kwon, Keon Woo
    Bae, Hyun Joo
    Park, Yun-Hee
    Song, Ho Young
    Chung, Chul-Woong
    CANCER RESEARCH, 2023, 83 (07)
  • [28] Antibody-drug conjugate targeting glypican-1 shows potent antitumor effect in pancreatic cancer
    Serada, Satoshi
    Nishigaki, Takahiko
    Sugase, Takahito
    Saito, Yurina
    Takahashi, Tsuyoshi
    Hiramatsu, Kosuke
    Fujimoto, Minoru
    Mori, Masaki
    Doki, Yuichiro
    Naka, Tetsuji
    CANCER RESEARCH, 2018, 78 (13)
  • [29] Development of a novel antibody-drug conjugate targeting endosialin/TEM-1: potent antitumor activity in sarcoma
    Sala, Gianluca
    Iacobelli, Stefano
    Capone, Emily
    PIccolo, Enza
    Sauniere, Jean-Fred
    Douet, Vanessa Vannucci
    CANCER RESEARCH, 2017, 77
  • [30] Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
    Yurkovetskiy, Aleksandr, V
    Bodyak, Natalya D.
    Yin, Mao
    Thomas, Joshua D.
    Clardy, Susan M.
    Conlon, Patrick R.
    Stevenson, Cheri A.
    Uttard, Alex
    Qin, LiuLiang
    Gumerov, Dmitry R.
    Ter-Ovanesyan, Elena
    Bu, Charlie
    Johnson, Alex J.
    Gurijala, Venu R.
    McGillicuddy, Dennis
    DeVit, Michael J.
    Poling, Laura L.
    Protopopova, Marina
    Xu, Ling
    Zhang, Qingxiu
    Park, Peter U.
    Bergstrom, Donald A.
    Lowinger, Timothy B.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (05) : 885 - 895
12345